Brian Korb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Driver charged with 3 murder counts in deadly McLean Co. crash Driver charged with 3 murder counts in deadly McLean Co. crash By Jill Lyman | April 9, 2021 at 3:59 PM CDT - Updated April 9 at 6:55 PM MCLEAN CO., Ky. (WFIE) - There’s an update on the March 18 crash in McLean County that killed three people. 24-year-old Dylan Cole Howard, of Calhoun. He faces the following charges: 1) Murder - Three (3) counts 2) Assault, 1st Degree 4) Operating Motor Vehicle Under the Influence of a Controlled Substance 5) Criminal Abuse, 1st Degree (Child 12 or under) 6) Trafficking in Controlled Subst...

Hopkinsville, KY, USA / WHOP 1230 AM | News Radio Apr 9, 2021 4:02 PM A Calhoun man who was involved in a fatal crash that killed three people in McLean County, including a local man, was charged with three counts of murder in relation to the incident. According to a news release from Kentucky State Police, 24-year old Dylan Howard of Calhoun is facing three counts of murder, first-degree assault, first-degree wanton endangerment, first-degree criminal child abuse, DUI, trafficking in a controlled substance and numerous traffic violations.  He is lodged in the Daviess County Detention Center...

Share this article Share this article RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100 TM: aviptadil) in the I-SPY COVID-19 Clinical Trial.  Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing multiple drugs for the treatment of patients with Critical COVID...

Search jobs 30-Dec-2020 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study 30.12.2020 / 07:00 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company") and NeuroRx, Inc. today announced the c...

Share this article Share this article RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief") today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100 TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. ...